PHARMACY

FDA approves 3 Teligent topical generics

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration approved three generics from New Jersey-based specialty generics company Teligent on the last day of 2016, the company announced Tuesday. 
 
The approvals were for the company’s generics of triamcinolone acetonide ointment, 1000,000 units/gram and 1mg/gram; clindamycin phosphate topical solution 1%; and flurandrenolide ointment, 0.05%. 
 
The company said that this brings its portfolio of internally developed topical generics that received approval in 2016 to nine, and that the three products approved have an addressable market of about $73.6 million. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan launches 3 generics

BY David Salazar
HERTFORDSHIRE, England and PITTSBURGH — Mylan last week capped off its 2016 by with the launch of three generics. The company on Thursday announced the launch of its generics of Concerta (methylphenidate hydrochloride) extended-release tablets, Zovia (ethynodiol diacetate and ethinyl estradiol, 1 mg/0.05 mg) tablets and Cerebyx (fosphenytoin sodium, 75 mg/mL) injection. 
 
Mylan’s generic of Concerta, a drug indicated to treat attention deficit hyperactivity disorder, will be available in 18-, 27-, 36- and 54-mg dosage strengths. The drug had U.S. sales of about $1.59 billion for the 12 months ended Oct. 31, 2016, according to QuintilesIMS data. The company did not include sales information for its generic of Zovia, an oral contraceptive. 
 
Mylan’s generic Cerebyx, indicated to treat certain types of sever seizures has also been launched and the drug saw U.S. sales of approximately $36.3 million for the 12 months ended Oct. 31, 2016. 
 
Mylan said it currently has 240 abbreviated new drug applications pending before the FDA, which it says represent some $95.6 billion in brand sales, with 41 of the ANDA’s potential first-to-file opportunities. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Dietary supplement sales expected to be strong at drug stores and pharmacies through 2025

BY Brian Berk

VALLEY COTTAGE, N.Y. — Sales of dietary supplements at pharmacies and drug stores are expected to grow by a robust global compound annual growth rate of 7.6% in terms of value during the 2015-2025 period, according to a new report by Future Market Insights.

The FMI report, entitled “Dietary Supplements Market: Global Industry Analysis and Opportunity Assessment, 2015-2025,” expects the overall global dietary supplements market to register a healthy 7.4% CAGR over the 11-year period, with North America contributing an increase of 7.2% on a CAGR basis. The global dietary supplements market is expected to grow by $252.1 billion from 2015-2025, the report adds.

The greatest source of strength will sports nutrition, a segment that will grow by 8.9% in the dietary supplements market over the forecast period.

The report also states both the vitamins and minerals segment and soft gels/pills segment are expected to “retain” their “dominance through 2025,” and the women’s segment of dietary supplements will be “the major contributor in terms of value in the dietary supplements market over the forecast period.”
The general wellbeing segment is also expected to be solid, with a forecast of CAGR of 6.9% over the forecast period, with general wellbeing and weight loss segments “expected to contribute maximum revenue shares to the global market over the forecast period.”

For more information about the report, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES